An interventional study of CeraVe Moisturizing Cream and La Roche Posay Lipikar AP+ Triple Repair Moisturizing Cream in Cancer, sponsored by Stanford University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Stanford University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to evaluate whether cosmeceutical topical moisturizers can help with skin dryness in participants with cancer experiencing a dermatological adverse event from cancer therapies. The main question it aims to answer is:
Does cosmeceutical topical moisturizers help with skin dryness?
Participants will:
10,832 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.
This study's planned enrollment of 50 is below the median of 60 across 7,712 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Stanford University is the lead sponsor of 2,173 studies on the registry; 433 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 207 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Nov 18, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will apply the following cosmeceutical topical moisturizers twice daily (once in the morning and once in the evening) for the duration of the study: 1. CeraVe Moisturizing Cream (once in the morning and once in the evening) 2. La Roche Posay Lipikar AP+ triple repair moisturizing cream (once in the morning and once in the evening) 3. La Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+) (once in the morning and once in the evening)
Other: CeraVe Moisturizing Cream · Other: La Roche Posay Lipikar AP+ Triple Repair Moisturizing Cream · Other: La Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+)
Moisturizer applied once in the morning and once in the evening.
Moisturizer applied once in the morning and once in the evening.
Balm applied once in the morning and once in the evening.
Change in Patient-Reported Skin Dryness Severity
Change in patient-reported skin dryness severity from baseline to follow-up visit (2-4 weeks) as measured by validated dryness severity scale (0-10 numerical rating scale where 0 = no dryness and 10 = severe dryness).
Time frame: From baseline visit to follow-up visit (approximately 2-4 weeks).
Time to improvement in dryness symptoms
The time from baseline to the first documented improvement in dryness symptoms, defined as either a ≥2-point reduction in dryness severity score from baseline or patient-reported meaningful improvement in dryness symptoms, whichever occurs first. Lower values indicate a faster improvement in symptoms.
Time frame: From baseline visit to follow-up visit (2-4 weeks).
Change in Stratum Corneum Hydration
Change in skin hydration from baseline to follow-up, measured using corneometry and reported in corneometry units (CU). Higher corneometry values indicate greater stratum corneum hydration. Positive changes from baseline reflect improved skin hydration, whereas negative changes indicate reduced hydration.
Time frame: From baseline visit to follow-up visit (2-4 weeks).
Change in Transepidermal Water Loss (TEWL)
Change in skin barrier function from baseline to follow-up, measured by transepidermal water loss (TEWL) and reported in g/h/m². TEWL quantifies the amount of water that passively evaporates through the skin. Lower TEWL values indicate improved skin barrier integrity and reduced water loss, while higher values indicate increased barrier disruption. Negative changes from baseline reflect improvement, whereas positive changes indicate worsening skin barrier function.
Time frame: From baseline visit to follow-up visit (2-4 weeks).
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Sep 2028, 22 months later.
Of 1,988 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 22 months is below that.
Counting every sponsor, half of 2,063 studies reached it within 29 months; a quarter within 13 and three quarters within 52.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 18, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.